首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.
【2h】

Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.

机译:口服荧光素血管造影:使用胶囊重新评估其相对安全性并评估最佳条件。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0.05%). A serious reaction may occur without warning in a patient with no history of atopy. There are no reports of oral fluorescein causing a serious reaction, and minor adverse effects are uncommon. A study was undertaken to determine optimum conditions for oral fluorescein angiography. Capsules proved more convenient than a solution for ingestion of fluorescein. A dose of 25 mg/kg body weight produced good quality angiograms in 75% of the patients. The best pictures were obtained by photographing the fundus after 40 and 60 minutes.
机译:静脉注射荧光素进行眼底血管造影的不良反应发生率很高(21%),但是严重(危及生命)反应的发生率却很低(0.05%)。没有特应性史的患者可能会发生严重反应,而不会发出警告。没有口服荧光素引起严重反应的报道,轻微的不良反应很少见。进行了一项研究以确定口服荧光素血管造影的最佳条件。胶囊比摄取荧光素的溶液更方便。 25 mg / kg体重的剂量可在75%的患者中产生高质量的血管造影照片。通过在40和60分钟后拍摄眼底可获得最佳照片。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号